A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Sodium Glycididazole in Concurrent Radiochemotherapy for the Treatment of Thoracic Esophageal Squamous Carcinoma
Esophageal cancer is one of the most frequent causes of cancer death in the world. The most
common type of esophageal cancer is squamous cell carcinoma (SCC) in China. Although
concurrent radiochemotherapy is recommended as the standard treatment for advanced
esophageal carcinoma, the local failure still reaches up to 44%-54%.
Sodium Glycididazole(CMNa) is a radiosensitive drug for hypoxic tumor cells. Clinical trials
showed that CMNa can improve local control rate and survival rate of esophageal cancer. This
study is going to confirm the efficacy and safety of CMNa in concurrent radiochemotherapy of
radiotherapy and 5-FU+DDP for esophageal squamous carcinoma.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
tumour local control rate
Lvhua Wang, Doctor
Cancer Hospital, Chinese Academy of Medical Science
China: Food and Drug Administration